Fate therapeutics highlights ipsc-derived, off-the-shelf car nk cell programs for multiple myeloma at 2022 ash annual meeting

Interim phase 1 data of ft576 bcma-targeted product candidate show clinical activity in initial single-dose escalation cohorts as monotherapy and in combination with daratumumab

FATE Ratings Summary

FATE Quant Ranking